Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin ) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text